Latest news with #PancreaticCancer
Yahoo
4 days ago
- Health
- Yahoo
Gastrointestinal cancers rising dramatically in people under 50
Gastrointestinal cancers, which include colorectal, stomach and pancreatic cancer, are rising dramatically in younger adults, though doctors aren't fully sure why. Even some of the possible causes require more research, they say. According to a review published Thursday in JAMA, gastrointestinal cancers have become the fastest-growing type of cancers diagnosed in adults younger than 50 in the U.S.. The review, one of the most comprehensive looks at gastrointestinal cancer trends, summarized the findings of major international and U.S. cancer databases, plus 115 papers on gastrointestinal cancers published from January 2014 to March 2025. The authors underscore the need for people to follow the screening guidelines for colorectal cancer, which suggest that people with an average risk start screening — usually a colonoscopy or stool test — at age 45. Since doctors don't routinely screen for pancreatic, stomach and esophageal cancers in the U.S., the authors also call for new ways to screen more people for these cancers. 'This really points to the importance of trying to improve screening and early detection,' said Dr. Kimmie Ng, the review's co-author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute. According to the review, colorectal cancer is by far the most common early-onset gastrointestinal cancer, with nearly 185,000 cases reported worldwide in 2022 and nearly 21,000 cases reported that same year in the U.S. Diagnoses in the U.S. have risen 2% annually in people younger than 50 since 2011, according to the American Cancer Society. 'It never used to happen in this age group, and now a very significant rise in 20, 30 and 40-year-olds are getting colon cancer,' said Dr. John Marshall, chief medical consultant at the nonprofit Colorectal Cancer Alliance, who was not involved in the research. In one of the most high-profile examples, actor Chadwick Boseman was diagnosed with colon cancer in 2016 and passed away of the disease four years later at age 43. Early-onset cases of pancreatic, stomach and esophageal cancers are also rising, according to the new study. Previous research has shown a disproportionate share of those gastrointestinal cancer diagnoses were among Black and Hispanic people. Pancreatic cancer is among the deadliest forms of cancer, with just 13% of patients surviving five years after their diagnosis. Because colorectal cancer is the most common, doctors said they have a better grasp of what might be contributing to these early-onset cases compared to others. 'If we can understand what's going on in colorectal [cancer], I think it would really provide a lot of guidance to help us understand the other GI tract cancers,' said Dr. Scott Kopetz, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center. Kopetz said there are likely multiple factors driving the increase in early-onset cases. 'The leading theory is that there is no single leading theory,' he said. Ng's new review in JAMA suggests that most gastrointestinal cancers in people under 50 are associated with lifestyle factors such as obesity, lack of exercise, poor diet, cigarette smoking or alcohol consumption. One study included in the review found that women who consumed more sugar-sweetened beverages during adolescence had a higher risk of developing early onset colorectal cancer. 'It's really what people were doing or exposed to when they were infants, children, adolescents that is probably contributing to their risk of developing cancer as a young adult,' Ng said. Health and Human Services Secretary Robert F. Kennedy Jr. has been vocal about the association between sugary beverages and health issues, including cancer. On Wednesday, President Donald Trump said Coca-Cola will start being made with cane sugar rather than corn syrup in the U.S., but the company did not commit to the change when asked about it by NBC News. Marshall said he suspects the rise in early-onset colorectal cancer could have something to do with changes in people's gut microbiomes — the bacteria that live in our gastrointestinal tracts. Diet, antibiotic use, microplastics and exposure to environmental chemicals likely all influence a person's gut bacteria, but scientists still don't have a clear understanding of what a healthy microbiome looks like nor how it affects our health. That is a booming area of research. Ng's review also found that 15% to 30% of people with early-onset gastrointestinal cancer carry hereditary genetic mutations that may have predisposed them to getting cancer at a young age. Because of that, she said, 'we do recommend that all young patients diagnosed under the age of 50 undergo testing for hereditary conditions.' Overall survival rates for gastrointestinal cancers have gotten better over time, due to improvements in treatment and screening. But Ng's review found that younger patients often have worse outcomes, despite typically receiving more treatments, including more surgery, radiation and aggressive combinations of chemotherapy, she said. One reason could be that primary care doctors may overlook symptoms such as abdominal pain, constipation, heartburn or reflux in younger patients, thereby delaying their diagnoses. 'My personal feeling is that it's because we're finding them at a more advanced stage, because people don't really think of colon or other GI cancers when they see a young person with these non-specific complaints,' said Dr. Howard Hochster, director of gastrointestinal oncology at Rutgers Cancer Institute and RWJBarnabas Health in New Jersey. But Ng said that even after controlling for the stage at which patients are diagnosed, young people still seem to have worse survival rates. 'This makes us wonder as researchers whether that means that the cancers that develop in younger people may be biologically different and more aggressive, or maybe less responsive to treatment,' she said. This article was originally published on Solve the daily Crossword
Globe and Mail
04-07-2025
- Health
- Globe and Mail
Chemotherapy Induced Nausea and Vomiting Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Chemotherapy Induced Nausea and Vomiting Pipeline Insight 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the Chemotherapy Induced Nausea and Vomiting pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Chemotherapy Induced Nausea and Vomiting Pipeline. Dive into DelveInsight's comprehensive report today! @ Chemotherapy Induced Nausea and Vomiting Pipeline Outlook Key Takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report In April 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie conducted a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose. DelveInsight's Chemotherapy Induced Nausea and Vomiting Pipeline report depicts a robust space with 4+ active players working to develop 6+ pipeline therapies for Chemotherapy Induced Nausea and Vomiting treatment. The leading Chemotherapy Induced Nausea and Vomiting Companies such as RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others. Promising Chemotherapy Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Akynzeo, Fosaprepitant Dimeglumine, Intranasal granisetron, Rolapitant, Granisetron, and others. Stay ahead with the most recent pipeline outlook for Chemotherapy Induced Nausea and Vomiting. Get insights into clinical trials, emerging therapies, and leading companies with Chemotherapy Induced Nausea and Vomiting @ Chemotherapy Induced Nausea and Vomiting Treatment Drugs Chemotherapy Induced Nausea and Vomiting Emerging Drugs Profile RHB-102: RedHill Biopharma RHB-102 is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, targeting potential indications including oncology support, acute gastroenteritis and gastritis, and IBS-D at two dose strengths, 12mg and 24mg. RedHill Biopharma entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals for RHB-102 for gastroenteritis & gastritis, IBS-D and oncology support. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting. APD403: Acacia Pharma APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in Barhemsys®. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. APD403 has successfully completed one proof-of-concept and one Phase II dose-ranging study demonstrating it is well tolerated and effective at preventing acute and delayed CINV. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting. The Chemotherapy Induced Nausea and Vomiting Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Nausea and Vomiting with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Nausea and Vomiting Treatment. Chemotherapy Induced Nausea and Vomiting Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chemotherapy Induced Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Nausea and Vomiting market Explore groundbreaking therapies and clinical trials in the Chemotherapy Induced Nausea and Vomiting Pipeline. Access DelveInsight's detailed report now! @ New Chemotherapy Induced Nausea and Vomiting Drugs Chemotherapy Induced Nausea and Vomiting Companies RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others. Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Chemotherapy Induced Nausea and Vomiting Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Chemotherapy Induced Nausea and Vomiting Treatment. Learn about new drugs, Chemotherapy Induced Nausea and Vomiting Pipeline developments, and key companies with DelveInsight's expert analysis @ Chemotherapy Induced Nausea and Vomiting Market Drivers and Barriers Scope of the Chemotherapy Induced Nausea and Vomiting Pipeline Report Coverage- Global Chemotherapy Induced Nausea and Vomiting Companies- RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others. Chemotherapy Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Akynzeo, Fosaprepitant Dimeglumine, Intranasal granisetron, Rolapitant, Granisetron, and others. Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Chemotherapy Induced Nausea and Vomiting Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chemotherapy Induced Nausea and Vomiting Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Chemotherapy Induced Nausea and Vomiting: Overview Pipeline Therapeutics Therapeutic Assessment Chemotherapy Induced Nausea and Vomiting– DelveInsight's Analytical Perspective Late Stage Products (Phase III) RHB-102: RedHill Biopharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) APD403: Acacia Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Chemotherapy Induced Nausea and Vomiting Key Companies Chemotherapy Induced Nausea and Vomiting Key Products Chemotherapy Induced Nausea and Vomiting- Unmet Needs Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion Chemotherapy Induced Nausea and Vomiting Analyst Views Chemotherapy Induced Nausea and Vomiting Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
South Wales Guardian
18-06-2025
- Health
- South Wales Guardian
NHS launches new drive to find more people with deadly pancreatic cancer
Hundreds of GP practices in England are being given extra funding to comb patient records looking for people with the disease, which has the lowest survival rate of all cancers. GPs and their teams will look for people over 60 who may have signs of the cancer, such as a recent diagnosis of diabetes and sudden weight loss. Figure suggest that around half of people diagnosed with pancreatic cancer have been diagnosed with type 1 or 2 diabetes recently. Family doctors taking part in the NHS England pilot will then contact patients and send them for urgent blood tests and CT scans to rule cancer in or out. Pancreatic cancer can have vague symptoms and is often diagnosed in the late stages. According to researchers, newly-diagnosed diabetes patients often have similar symptoms as a person with early-stage pancreatic cancer. This is because the cancer destroys the same insulin-producing cells that are also destroyed in diabetes. Around 10,500 people in the UK are diagnosed with pancreatic cancer every year and only around one in 20 survive the disease for 10 years or more. More than half of people die within three months of diagnosis. For the new three-year pilot, more than 300 GP practices in England will be involved, with all practices up and running by the autumn. Almost £2 million in targeted funding has been invested to help practices find people most at risk and give patients the best chance of being diagnosed early. Professor Peter Johnson, NHS national clinical director for cancer, said: 'Pancreatic cancer is responsible for so many deaths because patients don't usually notice symptoms until the cancer is at an advanced stage, which is why we need to find new ways to pick it up. 'Through initiatives like this and the upcoming 10-year health plan, the NHS is determined to go a step further – not just treat people at an advanced stage but to go out into communities and seek people out who might be unwell without any symptoms so we can provide people with the most effective treatment. 'The NHS is seeing and treating more people with cancer than ever, and early diagnosis is key to ensure patients have the best chance of receiving effective treatment. 'If your GP practice identifies you as at risk of pancreatic cancer, I urge you to come forward for testing as soon as possible.' Health minister Karin Smyth said: 'This targeted approach to identify people at risk of one of the most lethal cancers could give more people a fighting chance and spare the heartbreak of countless families.' We're delighted to see the Government commit to boosting clinical trials as part of their forthcoming 10 year plan. Clinical trials are a crucial treatment option for people with #PancreaticCancer & improving access to them could be key to driving up treatment & survival rates 🧪 — Pancreatic Cancer UK (@PancreaticCanUK) June 16, 2025 Alfie Bailey-Bearfield, head of influencing and health improvement at Pancreatic Cancer UK, said: 'Diagnosing more people with pancreatic cancer earlier, when the disease is most treatable, would make the single biggest difference to improving survival, so we are delighted to see significant further investment from NHS England towards that incredibly important goal. 'We're proud to have been involved in shaping this new case finding pilot, which will support GPs to proactively find people with pancreatic cancer among one of largest groups known to be at increased risk: those aged over 60, with new onset diabetes who have recently lost weight without trying to do so. 'Many of the people who are referred for a CT scan during the pilot will not have pancreatic cancer, but for those that do, the impact could be lifesaving. 'Subject to the pilot's success, we will be calling for this pilot to be expanded across the country to help give more people affected by the deadliest common cancer the very best chance of survival.' Previous research has shown that people over 50 with a new case of type 2 diabetes have a higher chance of being diagnosed with pancreatic cancer within three years.
North Wales Chronicle
18-06-2025
- Health
- North Wales Chronicle
NHS launches new drive to find more people with deadly pancreatic cancer
Hundreds of GP practices in England are being given extra funding to comb patient records looking for people with the disease, which has the lowest survival rate of all cancers. GPs and their teams will look for people over 60 who may have signs of the cancer, such as a recent diagnosis of diabetes and sudden weight loss. Figure suggest that around half of people diagnosed with pancreatic cancer have been diagnosed with type 1 or 2 diabetes recently. Family doctors taking part in the NHS England pilot will then contact patients and send them for urgent blood tests and CT scans to rule cancer in or out. Pancreatic cancer can have vague symptoms and is often diagnosed in the late stages. According to researchers, newly-diagnosed diabetes patients often have similar symptoms as a person with early-stage pancreatic cancer. This is because the cancer destroys the same insulin-producing cells that are also destroyed in diabetes. Around 10,500 people in the UK are diagnosed with pancreatic cancer every year and only around one in 20 survive the disease for 10 years or more. More than half of people die within three months of diagnosis. For the new three-year pilot, more than 300 GP practices in England will be involved, with all practices up and running by the autumn. Almost £2 million in targeted funding has been invested to help practices find people most at risk and give patients the best chance of being diagnosed early. Professor Peter Johnson, NHS national clinical director for cancer, said: 'Pancreatic cancer is responsible for so many deaths because patients don't usually notice symptoms until the cancer is at an advanced stage, which is why we need to find new ways to pick it up. 'Through initiatives like this and the upcoming 10-year health plan, the NHS is determined to go a step further – not just treat people at an advanced stage but to go out into communities and seek people out who might be unwell without any symptoms so we can provide people with the most effective treatment. 'The NHS is seeing and treating more people with cancer than ever, and early diagnosis is key to ensure patients have the best chance of receiving effective treatment. 'If your GP practice identifies you as at risk of pancreatic cancer, I urge you to come forward for testing as soon as possible.' Health minister Karin Smyth said: 'This targeted approach to identify people at risk of one of the most lethal cancers could give more people a fighting chance and spare the heartbreak of countless families.' We're delighted to see the Government commit to boosting clinical trials as part of their forthcoming 10 year plan. Clinical trials are a crucial treatment option for people with #PancreaticCancer & improving access to them could be key to driving up treatment & survival rates 🧪 — Pancreatic Cancer UK (@PancreaticCanUK) June 16, 2025 Alfie Bailey-Bearfield, head of influencing and health improvement at Pancreatic Cancer UK, said: 'Diagnosing more people with pancreatic cancer earlier, when the disease is most treatable, would make the single biggest difference to improving survival, so we are delighted to see significant further investment from NHS England towards that incredibly important goal. 'We're proud to have been involved in shaping this new case finding pilot, which will support GPs to proactively find people with pancreatic cancer among one of largest groups known to be at increased risk: those aged over 60, with new onset diabetes who have recently lost weight without trying to do so. 'Many of the people who are referred for a CT scan during the pilot will not have pancreatic cancer, but for those that do, the impact could be lifesaving. 'Subject to the pilot's success, we will be calling for this pilot to be expanded across the country to help give more people affected by the deadliest common cancer the very best chance of survival.' Previous research has shown that people over 50 with a new case of type 2 diabetes have a higher chance of being diagnosed with pancreatic cancer within three years.
Leader Live
18-06-2025
- Health
- Leader Live
NHS launches new drive to find more people with deadly pancreatic cancer
Hundreds of GP practices in England are being given extra funding to comb patient records looking for people with the disease, which has the lowest survival rate of all cancers. GPs and their teams will look for people over 60 who may have signs of the cancer, such as a recent diagnosis of diabetes and sudden weight loss. Figure suggest that around half of people diagnosed with pancreatic cancer have been diagnosed with type 1 or 2 diabetes recently. Family doctors taking part in the NHS England pilot will then contact patients and send them for urgent blood tests and CT scans to rule cancer in or out. Pancreatic cancer can have vague symptoms and is often diagnosed in the late stages. According to researchers, newly-diagnosed diabetes patients often have similar symptoms as a person with early-stage pancreatic cancer. This is because the cancer destroys the same insulin-producing cells that are also destroyed in diabetes. Around 10,500 people in the UK are diagnosed with pancreatic cancer every year and only around one in 20 survive the disease for 10 years or more. More than half of people die within three months of diagnosis. For the new three-year pilot, more than 300 GP practices in England will be involved, with all practices up and running by the autumn. Almost £2 million in targeted funding has been invested to help practices find people most at risk and give patients the best chance of being diagnosed early. Professor Peter Johnson, NHS national clinical director for cancer, said: 'Pancreatic cancer is responsible for so many deaths because patients don't usually notice symptoms until the cancer is at an advanced stage, which is why we need to find new ways to pick it up. 'Through initiatives like this and the upcoming 10-year health plan, the NHS is determined to go a step further – not just treat people at an advanced stage but to go out into communities and seek people out who might be unwell without any symptoms so we can provide people with the most effective treatment. 'The NHS is seeing and treating more people with cancer than ever, and early diagnosis is key to ensure patients have the best chance of receiving effective treatment. 'If your GP practice identifies you as at risk of pancreatic cancer, I urge you to come forward for testing as soon as possible.' Health minister Karin Smyth said: 'This targeted approach to identify people at risk of one of the most lethal cancers could give more people a fighting chance and spare the heartbreak of countless families.' We're delighted to see the Government commit to boosting clinical trials as part of their forthcoming 10 year plan. Clinical trials are a crucial treatment option for people with #PancreaticCancer & improving access to them could be key to driving up treatment & survival rates 🧪 — Pancreatic Cancer UK (@PancreaticCanUK) June 16, 2025 Alfie Bailey-Bearfield, head of influencing and health improvement at Pancreatic Cancer UK, said: 'Diagnosing more people with pancreatic cancer earlier, when the disease is most treatable, would make the single biggest difference to improving survival, so we are delighted to see significant further investment from NHS England towards that incredibly important goal. 'We're proud to have been involved in shaping this new case finding pilot, which will support GPs to proactively find people with pancreatic cancer among one of largest groups known to be at increased risk: those aged over 60, with new onset diabetes who have recently lost weight without trying to do so. 'Many of the people who are referred for a CT scan during the pilot will not have pancreatic cancer, but for those that do, the impact could be lifesaving. 'Subject to the pilot's success, we will be calling for this pilot to be expanded across the country to help give more people affected by the deadliest common cancer the very best chance of survival.' Previous research has shown that people over 50 with a new case of type 2 diabetes have a higher chance of being diagnosed with pancreatic cancer within three years.
